Intraocular drug delivery systems are developing to treat diabetic macular edema. Sustained release systems offer hope of long term treatment, compliance and little or no side effects.
Surmodics announces agreement with Genentech/Roche to combine proprietary drug delivery system with Lucentis (ranibizumab) for the treatment of wet macular degeneration.